Erbitux Gets Priority Review For Third-Line Colorectal Cancer Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
The sBLA, which includes studies showing an overall survival benefit, has an early October user fee date.
You may also be interested in...
Erbitux Approved As Monotherapy In Metastatic Colorectal Cancer Setting
Labeling for ImClone/Bristol’s epidermal growth factor receptor inhibitor is updated to include survival data as a single agent in colorectal cancer setting.
Erbitux Approved As Monotherapy In Metastatic Colorectal Cancer Setting
Labeling for ImClone/Bristol’s epidermal growth factor receptor inhibitor is updated to include survival data as a single agent in colorectal cancer setting.
Bristol Boosts ImClone Funding To Accelerate Erbitux Development
Bristol will invest an additional “several hundred million dollars” toward Erbitux late-stage clinical trials in brain, breast, bladder, esophageal, gastric and lung cancers.